![](/content/dam/global/hcpportal/master/images/homepage/products/incruse/2017/Incruse-Patient_profile.png)
“I’ve got used to often being short of breath, so I no longer go for my morning walks”
Age: 56 years
FEV1 predicted: 63%
mMRC: 2
GOLD B
Current treatment: As-needed short-acting β2agonist (SABA)
Gabrielle was diagnosed with chronic obstructive pulmonary disease (COPD) one year ago. Despite taking a SABA, she remains symptomatic.
For information on assessing your breathless patient, click here.
Continued breathlessness on exertion is proven to compromise patients’ daily life
- 70%–74% of patients with mild or moderate breathlessness experience limitations in routine activities, such as walking to the shops 1
- COPD may eventually limit patient mobility both inside and outside of the home, and is associated with feelings of panic, anxiety and depression 23
- Around 40% of patients are forced to retire early due to their symptoms 4
Indication
Incruse Ellipta (umeclidinium) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. 4
For more information on treating your patient who is already receiving maintenance therapy for their COPD but remains symptomatic, click here.
INCRUSE™ ™ y ELLIPTA™ Instructivo son marcas registradas del grupo de compañías GlaxoSmithKline